This trial is testing whether adding an experimental drug called LAM561 to standard treatment helps people newly diagnosed with an aggressive brain cancer called glioblastoma. About 144 participants will receive either LAM561 or a placebo pill along with their standard radiation …
Phase: PHASE2, PHASE3 • Sponsor: Laminar Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC